Medications to reduce breast cancer risk: a network meta-analysis of randomized controlled trials
Abstract Background Given the rising incidence of breast cancer, especially in premenopausal women, there is an urgent need to identify additional risk-reducing medications to accelerate prevention, as only a few are currently approved. We, therefore, performed network meta-analysis (NMA) to identif...
Saved in:
| Main Authors: | Ghazaleh Pourali, Minglu Liu, Supriya S. Sherpa, Angela Hardi, Chongliang Luo, Adetunji T. Toriola |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | Breast Cancer Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13058-025-02059-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Adjuvant endocrine treatment strategies for non-metastatic breast cancer: a network meta-analysisResearch in context
by: Andri Papakonstantinou, et al.
Published: (2025-03-01) -
Cardiovascular risks associated with adjuvant endocrine therapy in women with breast cancer: a population-based cohort study
by: Iokfai Cheang, et al.
Published: (2025-07-01) -
Selective estrogen receptor modulators and aromatase inhibitors in the treatment of functional male hypogonadism
by: Jakub Wydra, et al.
Published: (2025-08-01) -
Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer
by: Jaime D. Lewis, et al.
Published: (2014-11-01) -
Adjuvant hormone therapy in postmenopausal patients with locally advanced breast cancer: hope and reality
by: V. I. Borisov
Published: (2014-07-01)